Developing breakthrough treatments for psychiatric &
neurological disorders with a high unmet medical need

Advancing best in
class research

Patient populations suffering from headache disorders, OCD and substance use disorder have few effective treatment options and continue to have their medical needs unmet. At Ceruvia, we are partnering with some of the world’s leading experts in psychedelic research to help these patients and their families return to living their lives to the fullest.


Ceruvia’s drug candidate NYPRG-101 (BOL-148), is a non-hallucinogenic analog of lysergic acid diethylamide (LSD). First synthesized at Sandoz by Albert Hofmann in 1957, BOL-148 has shown the potential to replicate therapeutic effects of LSD without its psychoactive, hallucinogenic properties, thus making it an ideal candidate for the  development of therapies that can be delivered outside of a clinical setting.

Synthetic Psilocybin

Ceruvia’s drug candidate SYNP-101 (synthetic psilocybin), is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms. Numerous studies have demonstrated the potential of psilocybin to relieve the symptoms of a range of psychiatric and neurological disorders with an enduring effect.

Development Pipeline

Donors or investors with personal or professional interest in a specific program are encouraged to contact Ceruvia Lifesciences

* See sister firm B.More Inc.


Stay informed of Ceruvia news and research

Please enter Your Email

Skip to content